An isoform of HMGB1, ReHMGB1, both drives cellular senescence and is secreted by senescent cells. The molecular pathway that ReHMGB1 uses to cause these changes has been identified. Interfering with ...

Using multiple-biomarker analysis techniques allows for more accurate assessment of longevity interventions. Some DNA methylation biomarkers are more responsive to such interventions than others.

The FDA views aging as an inevitability, not a medical target. However, with Life Biosciences moving the first cellular reprogramming therapy into human trials this year, things might be changing ...

Global healthcare is operating on a mathematical impossibility. We currently spend trillions of dollars treating the downstream consequences of biological aging, such as diabetes, dementia, heart ...

The report, titled “Pathways to Longevity”, introduces several important longevity concepts to the general reader and is another sign that the field is coming of age and entering the mainstream. From ...

Dr. Andrea Maier, Oon Chiew Seng Professor in Medicine at the National University of Singapore, is a veteran geroscientist and one of the most familiar faces in the rising field of longevity medicine, ...

Life Biosciences is engaging in a clinical trial against two age-related eye diseases. This approach uses partial cellular reprogramming, which has never before been tried in humans. Life Biosciences ...

In aged wild-type mice and in mouse models of kidney disease, administering omega-3 polyunsaturated fatty acids improved several markers of function. Directly activating the target of these fatty ...

Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced that the U.S. Food and Drug ...

The number of clinical trials targeting Alzheimer’s disease is increasing. Most of the new candidate drugs target neurotransmitters, immune processes, tau, and other components of Alzheimer’s instead ...

Cyclarity Therapeutics is developing an affordable, plaque-busting small molecule that may be the cure for the world’s number one killer: cardiovascular disease. With human trials planned for this ...

The 2025 Longevity Summit Dublin was held in July, and we have the highlights from the event for you along with the latest research updates and news from the conference. The Summit was founded by ...